Skip to main content

Table 1 Characteristics of systematic reviews comparing triple therapy with different PPIs (n = 7)

From: Pharmacological regimens for eradication of Helicobacter pylori: an overview of systematic reviews and network meta-analysis

Author, year, country

Last search date

Disease

Interventionc

Comparatorc

No. of studies in MA

No. of patients in MA

Eradication rates

Eradication rates odds ratio (95 % CI) by ITT

Quality assessmentb

Gisbert et al. 2003-r Spain [43]

Sep 2002

HP infection; PUD/NUD/not reported

Rabeprazole

Omeprazole/Lansoprazole

12

2226

79 % vs. 77 %

1.15 (0.93–1.42)

+

Rabeprazole

Omeprazole

9

1475

77 % vs. 77 %

1.03 (0.81–1.32)

Rabeprazole

Lansoprazole

7

1095

82 % vs. 79 %

1.20 (0.87–1.64)

Vergara et al. 2003 Spain [51]

Sep 2002

HP infection

Omeprazole

Lansoprazole

4

1085

74.7 % vs. 76 %;

0.91 (0.69–1.21)a

+

Omeprazole

Rabeprazole

4

825

77.9 % vs. 81.2 %

0.81 (0.58–1.15)a

Omeprazole

Esomeprazole

2

833

87.7 % vs. 89 %

0.89 (0.58–1.35)a

Lansoprazole

Rabeprazole

3

550

81 % vs. 85.7 %

0.77 (0.48–1.22)a

Gisbert et al. 2004 Spain [44]

Jun 2003

HP infection; PUD +/−NUD

Esomeprazole

Omeprazole

4

1292

85 % vs. 82 %

1.19 (0.81–1.74)

+

Gisbert et al. 2004 Spain [45]

Sep 2002

HP infection; PUD +/−NUD

Pantoprazole

Omeprazole/Lansoprazole

7

1137

83 % vs. 81 %

1.00 (0.61–1.64)

+

Pantoprazole

Omeprazole

1

974

83 % vs. 82 %

0.91 (0.49–1.69)

Pantoprazole

Lansoprazole

2

258

78 % vs. 75 %

1.22 (0.68–2.17)

Wang et al. 2006 China [24]

Jul 2006

HP infection; DU, NUD, PUD

Esomeprazole

Omeprazole

11

2048

85.6 % vs. 81.6 %

1.30 (1.02–1.65)

0

Wang X et al. 2006 China [46]

2000–2005 (published date)

HP infection; PUD/NUD

Esomeprazole

Omeprazole/Pantoprazole

11

2146

86 % vs. 81 %

1.39 (1.09–1.75)

0

Esomeprazole

Omeprazole

10

1946

85 % vs. 82 %

1.29 (1.01–1.65)

Esomeprazole

Pantoprazole

1

200

94 % vs. 82 %

3.44 (1.30–9.07)

McNicholl et al. 2012 Spain [42]

Oct 2011

HP infection; naïve to therapy

Rabeprazole

Omeprazole/Lansoprazole/pantoprazole

21

2945

80.5 % vs. 76.2 %

1.21 (1.02–1.42)

0

Esomeprazole

Omeprazole/Lansoprazole/pantoprazole

12

2598

82.3 % vs. 77.6 %

1.32 (1.01–1.73)

Rabeprazole

Esomeprazole

5

1574

76.7 % vs. 78.7 %

0.90 (0.70–1.17)

  1. HP H.pylori, PPI proton pump inhibitor, PUD peptic ulcer disease, NUD non-ulcer dyspepsia, MA meta-analysis, ITT intention to treat, CI confidence interval
  2. a Peto OR is reported here
  3. b Quality assessment: high quality (++): majority of criteria met, little or no risk of bias and results unlikely to be changed by further research. Acceptable (+): most criteria met, some flaws in the study with an associated risk of bias and conclusions may change in the light of further studies. Low quality (0): either most criteria not met or significant flaws relating to key aspects of study design, and conclusions likely to change in the light of further studies
  4. c The antibiotics are the same type and same dose for each arm of the RCTs